The Filing Desk

Carlsmed

CARL · Nasdaq · Health Care · Financials, fiscal 2024 to 2025

CARL · Last close · November 19, 2026
$17.22
Value Carlsmed yourself

Carlsmed's revenue rose 85.9% to $50 million in fiscal 2025. Its operating margin was −60.5%, up from −88.8% a year earlier. Free cash flow was −$30 million. The diluted share count rose 249.7%.

CARLSMED, INC. Latest fiscal year ended December 31, 2025 10-K filed February 25, 2026 · 0001193125-26-071551 Updated
Revenue
$50M
85.9%
Operating margin
−60.5%
28.3 pts
Net income
−$30M
 
Free cash flow
−$30M
 
Return on equity
−209.9%
 
Market cap
$470M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What Carlsmed does

Carlsmed is a medical technology company that sells personalized implants and planning software for spine fusion surgery. Its aprevo platform uses AI-based software and a patient's imaging to design a surgical plan and interbody implants (spacers placed between vertebrae) shaped to fit that patient's spine. Each kit includes the custom implants and single-use surgical instruments. It has FDA clearance for lumbar and cervical uses.

It sells to hospitals and ambulatory surgical centers through its own sales team and independent agents, mainly in the U.S. All its revenue comes from aprevo implants. For 2025 it recognized revenue of $50.5 million. As of December 31, 2025, 253 surgeons had completed one or more procedures with the platform.

Carlsmed uses a small number of contract manufacturers to make, sterilize and ship the implants. It competes with companies that sell traditional stock implants.

Its biggest risks, as it describes them

  • Depending entirely on sales of aprevo implants and on surgeons adopting the platform.
  • A history of net losses, with more losses expected.
  • Relying on a limited number of contract manufacturers for its implants.
  • Needing to commercialize the platform for cervical spine surgery to grow.
  • Product liability claims and recalls.
From Carlsmed's annual report on Form 10-K, filed February 25, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Carlsmed lost money in fiscal 2025: a net loss of $30 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY24FY25
Cash and short-term investments40110
Debt incl. finance leases1515
Net debt (negative means net cash)−25−94
Net debt to EBITDA——
Debt to equity—0.2x
Interest coverage−18.3x−21.4x
Current ratio5.6x8.9x
Quick ratio5.5x8.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Carlsmed's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Carlsmed says to expect

  • Full year 2026: revenueRevenue for the full year 2026 is expected to be in the range of $78 million to $80 million, representing growth of over 56% at the midpoint.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 10, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Carlsmed shares on the open market, and 1 insider sold $2.6 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Mar 2, 2026Michael CordonnierCEO, President, DirectorSold197,855$13.29$2.6 millionForm 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY25
Piotroski F-score—
Rule of 4027.3%
Altman Z''4.88
Accruals ratio−0.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY25
Net income is positiveFail
Cash from operations is positiveFail
Return on assets rose—
Cash from operations exceeds net incomePass
Debt fell relative to assets—
Current ratio rosePass
Share count didn't riseFail
Gross margin rosePass
Revenue rose relative to assets—
F-score—
Companies that report no gross profit are scored on the other eight.

Compare

Put Carlsmed side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
CarlsmedFY2585.9%−60.5%−58.6%———
IRIDEXFY258.2%−4.9%−4.3%———Compare
Apyx MedicalFY259.9%−12.2%−17.2%−25.0%—4Compare
Shoulder InnovationsFY2549.6%−55.6%−76.1%———Compare
TriSalus Life SciencesFY2553.4%−59.7%−41.9%——3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

2 years of figures

Fiscal yearFY24FY25
Income statement
Revenue2750
Revenue growth—85.9%
Gross profit2038
Research and development1417
Operating income−24−31
Net income−24−30
Diluted EPS (US$)−6.11−2.12
Diluted shares (millions)414
Cash flow
Cash from operations−26−29
Capital expenditure01
Free cash flow−26−30
Dividends paid00
Share buybacks00
Acquisitions00
Stock-based compensation02
Balance sheet at fiscal year end
Cash and short-term investments40110
Debt incl. finance leases1515
Total assets52130
Total liabilities2631
Shareholders' equity−7199
Margins and ratios
Gross margin73.8%75.3%
Operating margin−88.8%−60.5%
Net margin−89.3%−58.7%
Free cash flow margin−94.4%−58.6%
Rule of 40 (growth + FCF margin)—27.3%
Return on capital——
Return on equity—−209.9%
Return on assets—−32.6%
Net debt to EBITDA——
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Carlsmed's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Carlsmed.